Glycaemic efficacy of an expanded dose range of dulaglutide according to baseline glycated haemoglobin (HbA1c) subgroup: Post hoc analysis of AWARD-11.

MLA

Frias, Juan P., et al. “Glycaemic Efficacy of an Expanded Dose Range of Dulaglutide According to Baseline Glycated Haemoglobin (HbA1c) Subgroup: Post Hoc Analysis of AWARD-11.” Diabetes, Obesity & Metabolism, vol. 23, no. 12, Dec. 2021, pp. 2819–24. EBSCOhost, https://doi.org/10.1111/dom.14533.

APA

Frias, J. P., Bonora, E., Cox, D. A., Bethel, M. A., Kwan, A. Y. M., Raha, S., & Malik, R. E. (2021). Glycaemic efficacy of an expanded dose range of dulaglutide according to baseline glycated haemoglobin (HbA1c) subgroup: Post hoc analysis of AWARD-11. Diabetes, Obesity & Metabolism, 23(12), 2819–2824. https://doi.org/10.1111/dom.14533

Chicago

Frias, Juan P, Enzo Bonora, David A Cox, M Angelyn Bethel, Anita Y M Kwan, Sohini Raha, and Raleigh E Malik. 2021. “Glycaemic Efficacy of an Expanded Dose Range of Dulaglutide According to Baseline Glycated Haemoglobin (HbA1c) Subgroup: Post Hoc Analysis of AWARD-11.” Diabetes, Obesity & Metabolism 23 (12): 2819–24. doi:10.1111/dom.14533.